Compare Kraft Heinz Co (KHC) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Neurocrine Biosciences Inc — how do they compare? Kraft Heinz Co trades at $24.27 (market cap $29.23B), while Neurocrine Biosciences Inc trades at $158.35 (market cap $16.46B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays a 6.49% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KHC | NBIX | |
|---|---|---|
Market Cap | $29.23B | $16.46B |
Sector | Consumer Staples | Health |
52-Week High | $28.06 | $185.50 |
52-Week Low | $21.21 | $123.10 |
Enterprise Value | $45.55B | $16.48B |
Dividend Yield | 6.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $24.93, down 1.54% on the day, with a bearish technical signal and mixed fundamentals. The company reported three consecutive quarterly earnings beats but faces profitability challenges with a negative net income margin of -13.64% and ROE of -8.78%. Recent news highlights CEO Steve Cahillane's turnaround strategy with increased marketing investments, while analysts remain cautious with only 11.43% buy ratings.
The stock presents a value opportunity with attractive valuation ratios (P/E 13.04, P/B 0.81) and 6.4% dividend yield, but significant risks include ongoing earnings erosion, competitive pressures, and high debt levels. The consensus price target of $24.00 suggests limited upside from current levels, requiring careful monitoring of the company's execution on its growth strategy.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
